Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review
Dec. 7, 2011
Affymax surged the most in the 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen and Johnson & Johnson for chronic kidney disease.
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing